Vaccine trial to help prevent head and neck cancer return
Part of Cancer clinical trials.
This Phase 2 study tests a Candida-based vaccine to help stop head and neck squamous cell cancer from coming back after curative treatment. If you are currently cancer-free on scans and exams, the trial may help train your immune system to lower recurrence risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You can understand the study and sign the consent form
- You are age 18 or older
- You have squamous cell cancer of the head and neck that has finished curative treatment within the last 120 days
- Your doctor says there is no evidence of active cancer on both exam and scans (no visible disease)
- You are willing and able to follow all study visit and treatment instructions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
This trial uses a blood test to look for tiny bits of tumor DNA after treatment for head and neck cancer. It aims to see if this test can detect any remaining cancer cells early, so you and your doctor can make informed decisions.
This early-phase (Phase 1b) study tests a vaccine designed to train the immune system to fight head and neck squamous cell carcinoma, plus standard immunotherapy. It may help some people by boosting the body’s anti-cancer immune response, but it mainly focuses on safety and finding the best approach.
This trial tests two medications given before surgery for head and neck cancer. The goal is to see if shrinking the tumor beforehand improves outcomes. If you have operable head and neck squamous cell cancer and are generally healthy, you may be eligible.
This Phase 1 trial tests cemiplimab (an immune system medicine) given with “induction” chemotherapy before the main treatment for locally advanced squamous cell head and neck cancer. It’s designed to see how well this treatment is tolerated and to learn about immune responses that may help future patients.
This trial studies the role of epigenetic marks in head and neck cancer to improve diagnosis and treatment. If you have been newly diagnosed with head and neck squamous cell carcinoma and have not yet received treatment, you may be eligible to participate.
Hear when a new Squamous Cell Carcinoma of Head and Neck trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.